Clinical Studies

The scientific evidence on VET-CXL with VETUVIR

VET-CXL®, or veterinary corneal cross-linking, was developed by Vision Engineering Italy to solve the problem of corneal infections in veterinary medicine. The treatment is also indicated for the treatment of inflammatory and degenerative diseases of the cornea. VET-CXL® is performed with VETUVIR® after applying EQUIRVIS® riboflavin eye drops to the cornea.

The VETUVIR® device is programmed to offer two treatment modes:

  • 30 mW/cm2 UV-A power density with 3 minutes irradiation time for the treatment of infectious keratitis and corneal ulcers. The mechanism of action promotes direct bactericidal action (peroxidation of the cell membranes of micro-organisms) and the strengthening of corneal tissue by counteracting bacterial collagenolytic activity (photo-polymerization of stromal proteins);
  • 10 mW/cm2 UV-A power density with 9 minutes of irradiation time for the treatment of bullous keratopathy. The mechanism of action favors the strengthening of the corneal tissue by counteracting the excessive edematous imbibition of the cornea.

Randomized Controlled Clinical Trial

The clinical study “Assessment of efficacy of corneal phototherapy with riboflavin and UV-A for treating septic corneal ulcers”, code VEI_vet01, has been completed at the Universities of Camerino and Perugia. Corneal phototherapy with VETUVIR has been shown to be 80% superior to standard of care for treating septic corneal ulcers in dogs and horses! The clinical outcome of the study have been presented at the main Scientific Congresses of Veterinary Medicine.

Learn more
An Assay System to Evaluate Riboflavin/UV-A Corneal Phototherapy Efficacy in a Porcine Corneal Organ Culture Model
Animals 2020, 10: 730
Assessment of UV-A/riboflavin corneal cross-linking efficacy for the treatment of experimentally induced corneal lesions in an ex vivo animal model
LXXII Convegno SISVET, 2018
Assessment of UV-A/riboflavin corneal cross-linking efficacy for the treatment of experimentally induced corneal lesions in an ex vivo animal model
International CXL experts meeting, 2017
Ozone-based eye drops in anterior segment pathologies: rationale and pre-clinical data
Ozone Therapy 2017